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Introduction
Excitatory amino acid (EAA) receptors play a major role in mediation of synaptic excitation in the central nervous system (CNS) and glutamate is the most abundant EAA in the CNS (Monaghan et at., 1989) . Glutamatergic transmission is mediated via three ligand-gated ionotropic receptors, iGluR's: N-methyl-D-aspartate (NMDA), aamino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and kainate (Monaghan et at., 1989) , and a G-protein coupled metabotropic receptor (mGluR; Conn and Pin, 1997) . Attenuation of glutamate transmission may be beneficial for CNS disorders, including cerebral ischemia, epilepsy, anxiety, pain and depression.
For example, anticonvulsant effects were demonstrated with competitive (Chapman et at., 1991a) and uncompetitive NMDA antagonists like phencyclidine (PCP; Hayes and Ba!ster, 1985; Chapman and Meldrum, 1989) , and the AMPA antagonist NBQX (Chapman et al., 1991b; Swedberg et al., 1995) . NMDA receptor blockade can cause hallucinations and other vivid psychoactive effects in humans (Aniline and Pitts, 1982; Bey et al., 2007) , mediates PCP-like discriminative effects in primates (Nicholson et al., 2007) and rats (Koek et al., 1990; Wiletts and Balster, 1988; Swedberg et al., 1995) , and maintains self-administration in animals (Nicholson et al., 2007) , whereas the AMPA antagonist NBQX caused no PCP-like discriminative effects (Swedberg et al., 1995) .
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anxiolytic (Porter et al., 2005) and analgesic effects in rodents (Montana et al., 2009) had shown anxiolytic effects in humans (Pecknold et al, 1980 (Pecknold et al, , 1982 Lapierre and Oyewumi, 1982) , and was dissimilar to the classic anxiolytic diazepam in being more psychostimulant (Itil et al., 1978; Friedmann et al., 1980) and causing hallucinations (Friedmann et al., 1980) . The more selective mGluR5 antagonist MPEP (2-methyl-6-(phenylethynyl)pyridine; Gasparini et al., 1999) had anxiolytic-like activity in rats (Ballard et al., 2005) and like SIB-1893 ((E)-2-methyl-6-styryl-pyridine) inhibited NMDA receptor activity in electrophysiological and pharmacological studies (O'Leary et al., 2000; Movsesyan et al., 2001) and had antagonistic effects on primate cocaine drug discrimination and self-administration (Lee at al., 2005) . The more recent mGluR5 antagonist MTEP (3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine) was more selective towards NMDA and other receptors and more potent in rat anxiety models compared to MPEP (Busse et al., 2004; Cosford et al., 2003) .
Psychoactive and hallucinatory effects of fenobam in humans (Friedmann et al., 1980; Pecknold et al, 1982) , MPEP antagonism of NMDA receptor mediated effects (O'Leary et al., 2000; Movsesyan et al., 2001) , and on cocaine self-administration and drug discrimination (Lee et al., 2005) , warrants further characterization of behavioral effects of mGluR5 antagonists.
In contrast to hyperactivity and ataxia often observed with NMDA antagonists such as PCP (Swedberg et al., 1995) , mGluR5 antagonists in our discovery program reduced spontaneous activity, caused flat body posture in rodents at higher doses in the Irwin screen (Irwin, 1968) or on spontaneous locomotor activity, but caused no other systematic behavioral effects or interacted with pentylenetetrazole convulsion thresholds (unpublished data).
In development of CNS active drugs, regulatory and safety aspects include investigation of potential for abuse liability, and applying a proactive abuse liability assessment strategy (Swedberg, 2013) , the present studies were designed to assess This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on January 28, 2014 as DOI: 10.1124/jpet.113.211185 at ASPET Journals on November 7, 2016 jpet.aspetjournals.org
Downloaded from
NMDA antagonist like discriminative effects of mGluR5 receptor antagonists in rat PCP drug discrimination, and to investigate the feasibility of establishing MTEP drug discrimination and assessing the selectivity of MTEP discrimination using other mGluR5 antagonists, NMDA antagonists and other drugs with psychoactive or hallucinogenic properties in humans. Cannabinoid (CB1) receptor agonists like δ -9-THC are psychoactive in humans (D'Souza et al., 2004) and animals (Wiley, 1999) .
LSD is a well known hallucinogenic (Passie et al., 2008) with discriminative effects in animals (Appel et al., 2004) . Arecoline, a cholinergic agonist and active ingredient in the betel nut is a CNS stimulant in humans (Bhat et al., 2010) and psychoactive in animals (Meltzer and Rosecrans, 1981) . Yohimbine, an α 2 adrenergic receptor antagonist can cause CNS excitation and dizziness and reinstatement of drug selfadministration (Fitzgerald, 2013) . Pentylenetetrazole is a nonspecific CNS stimulant (Bloom, 1990) and chlordiazepoxide a sedative anxiolytic (Rall, 1990) , both psychostimulant and sedative / anxiolytic in humans and animals, respectively.
Additionally, MTEP was compared to MPEP and PCP in a rat intravenous self administration procedure to evaluate the reinforcing potential of mGluR5
antagonism.
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that pressing any of the two levers would produce food, a drug lever and a no drug lever was assigned to each rat in a balanced fashion. From this point and on, each animal received either an injection of the training drug (Drug) or no injection (No drug), prior to training sessions, and were required to press the lever appropriate to the pretreatment received ("correct lever") in order to produce a food pellet. Animals were run on a single alternation schedule with an increase in the fixed ratio (FR) response requirement every other day until an FR10 was reached. Presses on the incorrect lever had no programmed consequences other than to reset the FR value on the correct lever, thus requiring the rats to emit 10 correct responses consecutively in order to obtain a food pellet. At FR10 a double-alternation schedule was introduced so that pairs of two consecutive drug (D) and no drug (N) sessions alternated (D, D, N, N, D, D, N, N etc) . A session lasted until 50 food pellets had been earned (equalling 50 trials) or until 15 min had elapsed, whichever occurred first. Rats were then trained to reach a criterion of 90% correct responding with no more than 9 responses on the incorrect lever prior to the first reinforcement in each session, for 8 consecutive sessions. The two sessions following immediately after the 8th criterion session were acquisition test sessions in which the training conditions (D and N) were tested and 10 consecutive responses on either lever would produce a food pellet (i.e. both levers were "correct"), and the same performance criteria were applied.
During testing, animals were run according to a single-alternation schedule (D, N, D, N etc.) and tests were interspersed between the training sessions (D, N). Formally: D, T, N, D, T, N, T, D, N, T etc. Test sessions were identical with training sessions, except that during tests both levers were correct and ten consecutive presses on any of the levers would produce a food pellet. Test sessions were typically run on Tuesdays and Fridays, provided that the animals performed according to the criterion on the training days. If training day performance fell below criteria for any rat on a 
Self-administration training
Rats were food trained on a fixed ratio (FR) 1 schedule of reinforcement. Following catheter implantation, intravenous self-administration was initiated with cocaine (0.5 mg/kg/inf), available on an FR5 schedule during daily 3-hour sessions. Once stable self-administration behavior was achieved (>10 delivered infusions and <15% variation in the number of infusions per rat during three consecutive sessions), vehicle was substituted for cocaine to cause extinction of responding (≤10 delivered infusions for three consecutive days). Dose response curves were generated for PCP (0.03 -1.0), MPEP (0.1-3.0) and MTEP (0.01-3.0; all doses in mg/kg/infusion) in separate groups of animals (n=8). Each dose was given until stable selfadministration behavior or extinction was reached and was preceded by a cocaine session to re-establish responding if the animal failed to respond on the previous dose.
Data analysis
Self-administration data from FR5 sessions are presented as the mean (±SEM) of the number of delivered infusions/3 hours and of intake (mg/kg)/3 hours, respectively.
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Statistical analysis on group values was performed using a one-way ANOVA followed by Dunn's multiple comparisons test (GraphPAD Prism, GraphPAD Software Inc., CA, USA) when appropriate. HCl (RBI) were dissolved in saline. Yohimbine HCl (Sigma-Aldrich) was dissolved in sterile water. Lysergic acid diethylamide (LSD; Lipomed) was dissolved in 5% acetic acid and 5% mannitol, and pH was adjusted to pH~5 by adding NaOH). MTEP, was administered in volumes of 10 ml/kg. MPEP was administered at 4ml/kg (PCP study) or 10 ml/kg (MTEP study, fenobam was administered at 5 ml/kg (PCP study) or 10 ml/kg (MTEP study), and all other drugs were given at 2 ml/kg. Doses given refer to the weight of the base. The following routes of administration and pretreatment times were used: PCP (i.p., 15 min), (+)-MK-801 (i.p., 15 min), ketamine (i.p., 15 min), When cocaine 0.5 mg/kg/infusion was available, rats self-administered a total mean (±SEM) of 46.6(7.8), 35.9 (1.6) and 34.8 (1.1) infusions in the PCP, MPEP and MTEP groups, respectively ( fig. 3 , A, C, E), whereas the same groups selfadministered saline at a mean (±SEM) of 5.2 (0.5), 4.4 (0.6) and 5.8 (0.9) infusions respectively. PCP (0.03 to 1.0 mg/kg/infusion) maintained self-administration and the number of infusions over the 3-h session generated yielded an inverted U shaped dose response curve with a maximal mean (±SEM) intake of 31.0(6.5) infusions at 0.1 mg/kg/infusion (statistically significant difference from vehicle, p=0.01; fig. 3, A) .
Drugs
The total amount of PCP self-administered increased with dose (fig 3, B ) reaching a maximal mean (±SEM) total intake of 10.6 (2.7) mg/kg over the 3-h session . MPEP (0.1 to 3 mg/kg/infusion; fig. 3 , C) and MTEP (0.01 to 3 mg/kg/infusion; fig. 3 ,E) did not maintain self-administration as the infusion rates were less than 7.5 and 6.5 respectively over the 3-h session. The MPEP and MTEP groups reached a maximal mean (±SEM) total intakes of 13.9 (1.6) and 6.0 (1.7) mg/kg respectively over the 3-h session at the highest doses ( fig. 3, D, F) . (Friedmann et al., 1980; Pecknold et al., 1982) and in vitro electrophysiology data showing modulation of functional effects of NMDA in rat neuronal cells by MPEP (Movsesyan et al., 2001) suggested the need to characterize the psychoactive effects of mGluR5 antagonists.
Since PCP causes psychotomimetic effects in man and is readily discriminated by animals and man, PCP drug discrimination procedures are used to predict psychotomimetic effects of novel glutamate antagonists (e.g. Koek et al., 1990; Swedberg et al., 1995) . Koek (1999) concluded that NMDA antagonists producing intermediate or full PCP-like discriminative effects in animals exert PCP-like effects in humans, while NMDA antagonists lacking PCP-like discriminative effects in animals appear not to produce PCP-like effects in man. Our data on NMDA antagonists in PCP trained rats are consistent with those and other findings, as is the lack of PCPlike discriminative effects of the AMPA antagonist NBQX (Swedberg et al., 1995) .
PCP in the present study yielded an ED 50 of 1.55 mg/kg, and a response rate increase to 127% of vehicle alone rates at the lowest dose causing 90% or greater PCP appropriate responding (2.8 mg/kg), in agreement with Swedberg et al. (1995) reporting a PCP ED 50 of 1.75 mg/kg and a response rate increase to 118% of vehicle alone rates at the lowest dose causing 90% or greater PCP appropriate responding.
Additionally, in the present study, (+)-MK-801 yielded an ED 50 of 0.18 mg/kg and (Nicholson et al., 1998) , whereas in monkeys memantine caused full PCP-appropriate responding without severe response rate suppression (Nicholson et al, 1998) . At the next lower dose of memantine (12.08 mg/kg) in the present study seven of eight rats responded and the mean PCP-appropriate responding was 36%.
The mGluR5 antagonists fenobam and MPEP caused non-dose dependent partial PCP-appropriate responding with maximal effects below 34% up to doses causing significant response rate reduction, whereas MTEP caused no PCP-appropriate responding up to a dose causing significant response rate reduction. These findings suggest that the partial PCP-like effects of fenobam and MPEP could be attributable to their lower selectivity with regards to NMDA antagonist activity (O'Leary et al., 2000; Movsesyan et al., 2001) , and the lack of PCP-like effects of MTEP due to its increased selectivity (Cosford et al., 2003) . (2000). In vitro profiling (Cosford et al., 2003) shows MPEP (18µM) bound more potently than MTEP (>300 µM) to NR2B receptors, which have been reported to mediate PCP-like discriminative effects in rats (Nicholson et al., 2007) . 7, 17.8 and 56.3 (Porter et al., 2005) . The corresponding in vitro and in vivo potencies and efficacies strengthen the conclusion that the MTEP-like discriminative effects of these compounds are attributable to mGluR5 receptor antagonism.
PCP caused approximately 27% METP-appropriate responding at the highest dose, 2.8 mg/kg, but not at lower doses, while (+)-MK-801 caused a partial, dose related increase with a maximum of 67% at the highest dose tested (0.19 mg/kg) and
reduced response rates to 74% of vehicle alone. Similarly, memantine caused a partial, dose related increase with a maximum of 54% MTEP-appropriate responding at a dose (12.95 mg/kg) causing response rate reduction to 47% of vehicle alone rates. These findings suggest that (+)-MK-801 and memantine and to some degree PCP in addition to their NMDA antagonist properties may to a lesser degree share some similar downstream functional effects consistent with notions that subtle differences in NMDA antagonist mechanisms may strongly impact neuronal effects (Johnson and Kotermanski, 2006) .
Chlordiazepoxide caused a partial, dose related increase in MTEP-appropriate responding peaking at 40% at a dose (56 mg/kg) lowering response rates to 49% of vehicle rates, and, although inconclusive, not inconsistent with observations of anxiolytic activity of MTEP.
LSD caused non dose related partial MTEP-like discriminative effects peaking at 35 to 47% depending on route of administration, but at a dose (0.3 mg/kg) that reduced response rates to 33 and 46 % of vehicle alone. Speculatively, the LSD findings may relate to the prominent and robust discriminative effects caused by MTEP and suggest some commonalities in the psychoactive properties, but further studies based on these findings need to be undertaken for any conclusions to be made. Yohimbine, arecoline, δ-9-THC and PTZ caused less than 20% MTEP appropriate responding up to doses causing substantial lowering of response rates, further demonstrating the selectivity of the MTEP drug discrimination assay.
It is concluded, that mGluR5 antagonist discriminative effects are selective and clearly dissimilar to other classes of psychoactive drugs even though in some cases weak partial non dose dependent effects occurred, and it is reemphasized that all non-mGluR5 antagonists causing MTEP-appropriate responding, did so at doses substantially suppressing response rates.
PCP but not MPEP or MTEP maintained self-administration suggesting different reinforcing properties of mGluR5-and NMDA-antagonists. Results suggest that while mGluR5 antagonists produce distinct psychoactive effects, mGluR5
antagonism may not cause abuse as reflected in lack of self-administration.
However, it is suggested per a proactive strategy for abuse liability assessment (Swedberg, 2013) that mGluR5 antagonists also be tested in primates (Weerts et al., 2007) to further explore and characterize these compounds.
In conclusion, the present data show that mGluR5 receptor antagonists and NMDA receptor antagonists produce distinctly different discriminative effects demonstrating that mGluR5-antagonism may produce psychoactive and psychotomimetic effects different from those caused by NMDA antagonism and other known mechanisms mediating psychotomimetic effects. It is concluded that the reported psychostimulant and hallucinogenic effects of mGluR5 antagonists in humans are most likely not caused by NMDA antagonism, but by a specific antagonism of mGluR5 receptors. 
